Botulinum toxin type A: Exploring new indications

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

The use of botulinum toxin has expanded in the last five years to include traditional neurological use against dystonia and spasticity, as well as the emerging use for headache, pain, neuropathy, myofascial pain, joint arthritis, otolaryngology, gastroenterology and genitourinary disorders. This review will focus on these emerging uses of botulinum toxin as reported in recent literature. The exploratory use of botulinum toxin for cervical dystonia, blepharospasm and spasticity in small trials and case reports, has led to its detailed study in larger placebo-controlled clinical trials. Although the use of botulinum toxin for new indications may benefit a specific subset of patients with refractory pain and disability, the reader must realize that this is an emerging area, generally limited by a lack of large, placebo-controlled studies.

Original languageEnglish (US)
Pages (from-to)671-682
Number of pages12
JournalDrugs of Today
Volume46
Issue number9
DOIs
StatePublished - Sep 1 2010
Externally publishedYes

Fingerprint

Type A Botulinum Toxins
Botulinum Toxins
Placebos
Blepharospasm
Torticollis
Intractable Pain
Dystonia
Controlled Clinical Trials
Otolaryngology
Arthralgia
Gastroenterology
Arthritis
Headache
Pain

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Botulinum toxin type A : Exploring new indications. / Brashear, Allison.

In: Drugs of Today, Vol. 46, No. 9, 01.09.2010, p. 671-682.

Research output: Contribution to journalReview article

@article{63674b8c6a494997886991aa40436ba0,
title = "Botulinum toxin type A: Exploring new indications",
abstract = "The use of botulinum toxin has expanded in the last five years to include traditional neurological use against dystonia and spasticity, as well as the emerging use for headache, pain, neuropathy, myofascial pain, joint arthritis, otolaryngology, gastroenterology and genitourinary disorders. This review will focus on these emerging uses of botulinum toxin as reported in recent literature. The exploratory use of botulinum toxin for cervical dystonia, blepharospasm and spasticity in small trials and case reports, has led to its detailed study in larger placebo-controlled clinical trials. Although the use of botulinum toxin for new indications may benefit a specific subset of patients with refractory pain and disability, the reader must realize that this is an emerging area, generally limited by a lack of large, placebo-controlled studies.",
author = "Allison Brashear",
year = "2010",
month = "9",
day = "1",
doi = "10.1358/dot.2010.46.9.1524356",
language = "English (US)",
volume = "46",
pages = "671--682",
journal = "Drugs of Today",
issn = "1699-3993",
publisher = "Prous Science",
number = "9",

}

TY - JOUR

T1 - Botulinum toxin type A

T2 - Exploring new indications

AU - Brashear, Allison

PY - 2010/9/1

Y1 - 2010/9/1

N2 - The use of botulinum toxin has expanded in the last five years to include traditional neurological use against dystonia and spasticity, as well as the emerging use for headache, pain, neuropathy, myofascial pain, joint arthritis, otolaryngology, gastroenterology and genitourinary disorders. This review will focus on these emerging uses of botulinum toxin as reported in recent literature. The exploratory use of botulinum toxin for cervical dystonia, blepharospasm and spasticity in small trials and case reports, has led to its detailed study in larger placebo-controlled clinical trials. Although the use of botulinum toxin for new indications may benefit a specific subset of patients with refractory pain and disability, the reader must realize that this is an emerging area, generally limited by a lack of large, placebo-controlled studies.

AB - The use of botulinum toxin has expanded in the last five years to include traditional neurological use against dystonia and spasticity, as well as the emerging use for headache, pain, neuropathy, myofascial pain, joint arthritis, otolaryngology, gastroenterology and genitourinary disorders. This review will focus on these emerging uses of botulinum toxin as reported in recent literature. The exploratory use of botulinum toxin for cervical dystonia, blepharospasm and spasticity in small trials and case reports, has led to its detailed study in larger placebo-controlled clinical trials. Although the use of botulinum toxin for new indications may benefit a specific subset of patients with refractory pain and disability, the reader must realize that this is an emerging area, generally limited by a lack of large, placebo-controlled studies.

UR - http://www.scopus.com/inward/record.url?scp=79955902288&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955902288&partnerID=8YFLogxK

U2 - 10.1358/dot.2010.46.9.1524356

DO - 10.1358/dot.2010.46.9.1524356

M3 - Review article

C2 - 20967299

AN - SCOPUS:79955902288

VL - 46

SP - 671

EP - 682

JO - Drugs of Today

JF - Drugs of Today

SN - 1699-3993

IS - 9

ER -